U.S., Jan. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07359404) titled 'Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC' on Dec. 12, 2025.
Brief Summary: This is a single-arm, multicenter, Phase II clinical study aiming to explore the efficacy and safety of Sacituzumab Govitecan combined with Bevacizumab as a second-line or later treatment for patients with metastatic triple-negative breast cancer (mTNBC). The study will be conducted in 6-8 centers in China.
The study is divided into two phases: a Safety Run-in Phase and a Dose Expansion Phase.
In the Safety Run-in Phase (3-12 patients), three dose levels are planned to determine the recommended dose. The starting dose (Level 1) is Sacituzum...